9 active not recruiting, 4 recruiting, 3 withdrawn, 2 completed. 10 Phase 1, 3 Early Phase 1, 3 Phase 2, 2 Not applicable, 2 Phase 3.
Follow Stage IV Primary Peritoneal Cancer AJCC v8: new trials by email Literature Review of Stage IV Primary Peritoneal Cancer AJCC v8 trials Research Report on Stage IV Primary Peritoneal Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study Behavioral Intervention, Best Practice, Biospecimen Collection - Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma | Not applicable | Recruiting | Roswell Park Cancer Institute | 120 | 2025-06-04 | 2026-01-06 |
| Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Alpha-type-1 Polarized Dendritic Cells, Autologous Natural Killer Cell-like CTLs - Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8 | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2023-12-15 | 2023-11-22 | |
| ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer Wee1 Inhibitor ZN-c3 - Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-07-30 | 2023-05-06 | |
| PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Biopsy, Pegylated SN-38 Conjugate PLX038, Computed Tomography - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 20 | 2022-09-14 | 2026-07-16 |
| Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer Biopsy Procedure, Carboplatin, Ipatasertib - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 25 | 2022-09-08 | 2026-09-22 |
| Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer Carboplatin, Cisplatin, Cytoreductive Surgery - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma | Early Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 35 | 2022-06-13 | 2026-08-17 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel - Advanced Breast Carcinoma, Advanced Endometrial Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-04-29 | 2026-07-16 |
| Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer Dostarlimab, Niraparib, Biopsy - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Active not recruiting | University of Washington | 18 | 2021-10-18 | 2026-08-20 |
| Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Behavioral Counseling, Nutritional Supplement Drink, Physical Activity - Advanced Ovarian Carcinoma, Stage IIIC Fallopian Tube Cancer AJCC v8 | Not applicable | Completed | Mayo Clinic | 90 | 2021-10-05 | 2025-08-08 |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2021-06-01 | 2026-07-31 |
| Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer Abexinostat Tosylate, Fulvestrant, Palbociclib - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 | Withdrawn | Pamela Munster | 2021-03-31 | 2021-05-18 | |
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial Chemotherapy, Laparotomy, Minimally Invasive Surgery - Advanced Ovarian Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Recruiting | M.D. Anderson Cancer Center | 580 | 2020-08-05 | 2026-09-14 |
| Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Quality-of-Life Assessment, Radiation Therapy, Talazoparib - Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 24 | 2019-09-26 | 2026-03-11 |
| Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Biopsy Procedure, Biospecimen Collection, Carboplatin - Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma | Phase 3 | Active not recruiting | NRG Oncology | 450 | 2019-09-20 | 2026-03-24 |
| Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery Chemotherapy, Olaparib, Therapeutic Conventional Surgery - BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2019-06-07 | 2026-08-12 |
| Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer PRGN-3005 UltraCAR-T cells - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Active not recruiting | Precigen, Inc | 71 | 2019-04-30 | 2024-11-08 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2018-09-21 | 2025-05-22 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 15 | 2017-07-14 | 2026-07-08 |
Fallopian Tube Neoplasms (18) · Ovarian Neoplasms (18) · Endometrial Neoplasms (4) · Breast Neoplasms (3) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Uterine Cervical Neoplasms (2) · Carcinoma, Endometrioid (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Melanoma (1) · Peritoneal Neoplasms (1) · Sarcoma, Synovial (1) · Triple Negative Breast Neoplasms (1) · Vaginal Neoplasms (1)
Adnexal Diseases (18) · Endocrine Gland Neoplasms (18) · Endocrine System Diseases (18) · Fallopian Tube Diseases (18) · Female Urogenital Diseases (18) · Female Urogenital Diseases and Pregnancy Complications (18) · Genital Diseases (18) · Genital Diseases, Female (18) · Genital Neoplasms, Female (18) · Gonadal Disorders (18) · Neoplasms (18) · Neoplasms by Site (18) · Ovarian Diseases (18) · Urogenital Diseases (18) · Urogenital Neoplasms (18)
Biopsy (5) · Specimen Handling (5) · Taxes (4) · Carboplatin (3) · Paclitaxel (3) · X-Rays (3) · Behavior Therapy (2) · Drug Therapy (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · BAY 1895344 (1) · CTLA-4 Antigen (1) · Cisplatin (1) · Cyclophosphamide (1)
M.D. Anderson Cancer Center (5) · Roswell Park Cancer Institute (3) · Mayo Clinic (2) · National Cancer Institute (NCI) (2) · NRG Oncology (1) · OHSU Knight Cancer Institute (1) · Ohio State University Comprehensive Cancer Center (1) · Pamela Munster (1) · Precigen, Inc (1) · University of Washington (1)
United States (16) · Canada (2) · Ireland (1) · Italy (1) · Mexico (1) · Netherlands (1) · Peru (1) · Puerto Rico (1) · South Korea (1)
Amanda N Fader (1) · Amanika A. Kumar, MD (1) · Amir A Jazaeri (1) · Amy R. Lankford, PhD (1) · Andrea E. Wahner Hendrickson, M.D. (1) · Apostolia M Tsimberidou (1) · Elizabeth M. Swisher (1) · Emese Zsiros (1) · Emese Zsiros, MD, PhD (1) · Evthokia Hobbs, M.D. (1) · Floor Backes, MD (1) · James M Cleary (1) · Jose A Rauh-Hain (1) · Katherine C Fuh (1) · Lilie L Lin (1)
PMID 38471508, PMID 39570589, PMID 40058134
P50CA159981 (2), U10CA180868 (2), P30CA016056 (1), P50CA136393 (1), R01CA164333 (1), UM1CA186709 (1)